About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in New York State | 14,718 Studies Near You | Clareo Health

Clinical Trials LocationsNew York State

Clinical Trials in New York State

Discover 14,718 clinical trials near New York. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3021-3040 of 14,718 trials

COMPLETEDPhase 262 miles

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

NCT04675151

The objectives of this study are: To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia

Ocuphire Pharma, Inc.150 participantsStarted Feb 2021

Laguna Hills, California, United States • Newport Beach, California, United States • Crystal River, Florida, United States +14 more locations

COMPLETEDPhase 268 miles

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT06203002

Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/

Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals496 participantsStarted Nov 2023

Anniston, Alabama, United States • Birmingham, Alabama, United States • Daphne, Alabama, United States +105 more locations

Find Trials by Condition in New York State

Breast Cancerin New York State Lung Cancerin New York State Prostate Cancerin New York State Colorectal Cancerin New York State Melanomain New York State Leukemiain New York State Lymphomain New York State Pancreatic Cancerin New York State Ovarian Cancerin New York State Brain Cancerin New York State

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2/392 miles

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

NCT05729373

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.

Generalized Anxiety Disorder

Otsuka Pharmaceutical Development & Commercialization, Inc.434 participantsStarted Mar 2023

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Culver City, California, United States +80 more locations

Enrolling By InvitationNA98 miles

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

NCT05932615

The objective of ENVISION is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Valve Implantation (TAVI) System for treating patients with symptomatic, severe native aortic stenosis who are considered intermediate or low risk for surgical mortality. The trial will also evaluate the safety and effectiveness of the Navitor TAVI System in a valve-in-valve (ViV) application in patients with symptomatic heart disease due to failure of a surgical or transcatheter bioprosthetic aortic valve who are at high or greater surgical risk.

Aortic Valve StenosisHeart Valve DiseasesAortic Valve Disease+1 more

Abbott Medical Devices1,500 participantsStarted Mar 2024

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Fontana, California, United States +63 more locations

COMPLETEDPhase 2103 miles

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

NCT01908777

The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.

T Cell Non-Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center47 participantsStarted Jul 2013

Tampa, Florida, United States • Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States +7 more locations

RECRUITINGPhase 4105 miles

Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

NCT05383274

Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.

Urethral Stricture

Urotronic Inc.34 participantsStarted Feb 2022

Little Rock, Arkansas, United States • Orlando, Florida, United States • Tampa, Florida, United States +6 more locations

COMPLETEDPhase 3107 miles

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606

This study looks at the safety and effectiveness of Aviptadil in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Aviptadil plus current standard of care (SOC), or with placebo plus current SOC.

National Institute of Allergy and Infectious Diseases (NIAID)471 participantsStarted Apr 2021

Tucson, Arizona, United States • Fresno, California, United States • Loma Linda, California, United States +37 more locations

COMPLETEDPhase 1112 miles

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

NCT02290951

This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.

Non-Hodgkin LymphomaChronic Lymphocytic Leukemia

Regeneron Pharmaceuticals200 participantsStarted Jan 2015

Orange, California, United States • Stanford, California, United States • Tampa, Florida, United States +19 more locations

RECRUITINGPhase 1112 miles

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

NCT06733441

The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.

Treeline Biosciences, Inc.50 participantsStarted Dec 2024

Stanford, California, United States • St Louis, Missouri, United States • New York, New York, United States +2 more locations

RECRUITINGPhase 3112 miles

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Pancreas CancerPeutz-Jeghers Syndrome (PJS)Gene Mutation+2 more

Johns Hopkins University9,000 participantsStarted Jan 2014

New Haven, Connecticut, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States +6 more locations

TERMINATEDPhase 1118 miles

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

NCT05429502

This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors, including medulloblastoma (MB), high-grade glioma (HGG), malignant rhabdoid tumors (MRT), and rhabdomyosarcoma (RMS).

Novartis Pharmaceuticals12 participantsStarted Dec 2022

Boston, Massachusetts, United States • New Hyde Park, New York, United States • Memphis, Tennessee, United States +3 more locations

RECRUITINGNA120 miles

The Periviable GOALS Decision Support Tool

NCT05264779

The Periviable GOALS (Getting Optimal Alignment around Life Support) decision support tool (DST) is meant to facilitate informed shared decision-making regarding neonatal resuscitation for families facing the threat of a periviable delivery (deliveries occurring between 22 0/7 - 25 6/7 weeks gestational age). It is designed for parents to review independent of their clinician, and is intended to supplement, not replace, clinician counseling. The focus of the DST is the provision of patient-centered outcomes information and assistance with values clarification regarding neonatal outcomes. This is a multisite, randomized controlled trial to test the effect of the Periviable GOALS DST on shared decision making and decision satisfaction. The investigators hypothesize that participants who utilize the GOALS DST will have improved shared decision making and higher decision satisfaction.

Pregnancy PretermPremature BirthPregnancy Complications+2 more

Indiana University216 participantsStarted Jun 2022

San Diego, California, United States • San Francisco, California, United States • New Haven, Connecticut, United States +7 more locations

TERMINATEDPhase 2120 miles

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

NCT05370521

An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens

Polycystic Ovary Syndrome

Spruce Biosciences27 participantsStarted May 2022

Sacramento, California, United States • San Francisco, California, United States • New Haven, Connecticut, United States +18 more locations

TERMINATED153 miles

Natural History of Netherton Syndrome

NCT05902663

The goal of this non-interventional study (NIS) is to collect real-world data to describe the natural history of Netherton Syndrome (NS).

Netherton Syndrome

Boehringer Ingelheim12 participantsStarted Oct 2024

Rancho Santa Margarita, California, United States • Chicago, Illinois, United States • Philadelphia, Pennsylvania, United States +1 more locations

TERMINATEDPhase 1/2153 miles

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

NCT04494256

The ALSpire Study is a clinical trial evaluating the investigational drug BIIB105 in adults living with amyotrophic lateral sclerosis (ALS). The ALSpire Study consists of two parts: * Part 1: 6-month placebo-controlled study. During Part 1, participants are randomly assigned to receive either BIIB105 or placebo in a 3:1 or 2:1 ratio (depending on the participant's assigned Cohort). * Part 2: up to 3-year long-term open-label extension. During Part 2, all participants receive BIIB105. The objectives of the study are to evaluate: * The safety and tolerability of BIIB105 in people with ALS * What the body does to BIIB105 (also called "pharmacokinetics") * What BIIB105 does to the body (also called "pharmacodynamics") * Whether BIIB105 can slow the worsening of clinical function

Amyotrophic Lateral Sclerosis

Biogen99 participantsStarted Sep 2020

Phoenix, Arizona, United States • La Jolla, California, United States • Palo Alto, California, United States +14 more locations

RECRUITINGNA199 miles

Ultrasound Stimulation for Patients in a Disorder of Consciousness

NCT06939348

The overall aim of this study is to develop an intervention that can help recovery in patients surviving severe brain injury but failing to fully recover. In particular, this multicenter project aims to (1) establish short-term efficacy of tFUS as a therapeutic to promote recovery in patients with prolonged DoC as compared to sham treatment, (2) establish dose-related safety and efficacy of tFUS as a therapeutic intervention in prolonged DoC patients and (3) explore preliminary predictors and biomarkers of susceptibility and response to thalamic sonication.

Consciousness DisordersDisorders of Consciousness Due to Severe Brain Injury

University of California, Los Angeles60 participantsStarted Apr 2025

Los Angeles, California, United States • Pomona, California, United States • Boston, Massachusetts, United States +1 more locations

RECRUITINGPhase 2199 miles

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

NCT06747858

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

Cystic FibrosisCFTR Gene Mutation

Arcturus Therapeutics, Inc.12 participantsStarted Dec 2024

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +8 more locations

COMPLETEDPhase 3199 miles

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090

The purpose of this study is to explore the overall safety profile and durability of efficacy of Engensis (VM202) in painful diabetic peripheral neuropathy. All subjects still in follow-up for the VMDN-003 study or who have completed the Day 270 visit within the prior 90 days will be approached to enroll in the long-term safety extension study.

Painful Diabetic NeuropathyDiabetic Neuropathy, Painful

Helixmith Co., Ltd.101 participantsStarted Feb 2019

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Sacramento, California, United States +11 more locations

COMPLETEDPhase 2217 miles

Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

NCT05421598

This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with amlitelimab in adult participants with moderate-to-severe asthma. Study details include: * The study duration (per participant) will be up to approximately 76 weeks for participants not going into LTS study and will be up to approximately 64 weeks for participants going into LTS study. * The randomized treatment duration will be up to approximately 60 weeks. * The scheduled number of visits will be 13.

Sanofi446 participantsStarted Jun 2022

La Jolla, California, United States • Los Angeles, California, United States • San Jose, California, United States +110 more locations

RECRUITINGPhase 2347 miles

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229

The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms and impacts on daily living as well as on functional lower extremity strength and endurance. Additionally, the study evaluates the safety and tolerability of KL1333.

Primary Mitochondrial Disease

Abliva AB180 participantsStarted Dec 2022

Akron, Ohio, United States • Houston, Texas, United States • Brussels, Belgium +20 more locations

PreviousPage 152 of 736Next

Diabetes

in New York State

Heart Diseasein New York State